Tonix Pharmaceuticals Holding Corp. announced it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market. Trading on the higher tier is expected to begin at the open of market on March 3, 2026, under the existing ticker symbol "TNXP." The move reflects the company's compliance with the Nasdaq Global Select Market's more stringent financial and corporate governance requirements and is expected to enhance institutional visibility, liquidity and broader market recognition. Management described the uplisting as an important milestone as the company continues to focus on growth and shareholder value creation.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system and immunology treatments in areas of high unmet medical need. TONMYA, the company's recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
The uplisting to the Nasdaq Global Select Market represents a significant validation of Tonix's financial health and corporate governance practices. For business leaders and investors, this development signals that the company has met rigorous standards typically associated with larger, more established public companies. The enhanced visibility on a premier market tier could attract more institutional investors and potentially improve stock liquidity, which is crucial for companies seeking to raise capital for research and development.
For the biotechnology industry, Tonix's successful uplisting demonstrates that commercial-stage biotech firms with approved products and diverse pipelines can achieve recognition on major market exchanges. This could encourage similar companies to pursue similar paths as they mature. The company's focus on central nervous system disorders and immunology addresses significant healthcare challenges, with TONMYA representing an important advancement for fibromyalgia patients who have had limited treatment options for over a decade and a half.
The implications extend beyond financial markets to healthcare innovation. As Tonix advances its clinical trials for TONMYA in major depressive disorder and acute stress disorder, and progresses its immunology pipeline, the company's enhanced market position could provide additional resources to accelerate development of treatments for conditions with substantial unmet needs. The full press release regarding the Nasdaq listing approval can be viewed at https://ibn.fm/uDmmW.
